StockNews.AI
OSUR
StockNews.AI
118 days

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

1. OraSure's Q1 2025 earnings call scheduled for May 7, 2025. 2. Webcast available for investors on the company website. 3. OraSure focuses on improving healthcare access and quality. 4. Company develops rapid diagnostic tests and sample management solutions. 5. OraSure's products are sold globally to various healthcare entities.

4m saved
Insight
Article

FAQ

Why Neutral?

Earnings calls can vary in their impact; past calls have shown mixed reactions.

How important is it?

The earnings call may provide critical financial insights impacting investor sentiment.

Why Short Term?

Immediate market reaction expected post-earnings call results on May 7, 2025.

Related Companies

DNASHERAABB
April 23, 2025 16:05 ET  | Source: OraSure Technologies, Inc. BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately one year. For participants interested in asking questions during the conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email. https://register-conf.media-server.com/register/BI59f66a2310854c78a00d41966823f810 About OraSure Technologies, Inc. OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com

Related News